Impact of serotonin on tumour growth

Annals of Medicine

Volumn 32, Issue 3, 2000, Pages 187-194

  Vicaut, Eric ^a   Laemmel, Elisabeth ^a   Stücker, Olivier ^a  

^a HÔPITAL FERNAND WIDAL   (France)

Author keywords

Anticancer drugs; Growth factors; Tumour vasculature

Indexed keywords

ANTINEOPLASTIC AGENT; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

BLOOD FLOW; CELL PROLIFERATION; HUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION; VASOCONSTRICTION;

EID: 0034014410     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890008998826     Document Type: Review

References (48)

1. Seuwen K, Pouyssegur J. Serotonin as a growth factor. Biochem Pharmacol 1990; 39: 985-90.
2. Kavanaugh WM, Williams LT, Ives HE, Coughlin SR. Serotonin-induced deoxyribonucleic acid synthesis in vascular smooth muscle cells involves a novel, pertussis toxin-sensitive pathway. Mol Endocrinol 1988; 2: 599-605.
3. i-protein. Nature 1988; 335: 254-6.
4. Horai T, Nishihara H, Tateishi R, Matsuda M, Hattori S. Oat-cell carcinoma of the lung simultaneously producing ACTH and serotonin. J Clin Endocrinol Metab 1973; 37: 212-3.
5. Cattaneo MG, Codignola A, Vicentini LM, Clementi F, Sher E. Nicotine stimulates a serotoninergic autocrine loop in human small-cell lung carcinoma. Cancer Res 1993; 53: 5566-8.
6. Cattaneo MG, Palazzi E, Bondiolotti G, Vicentini LM. 5-HT1D receptor type is involved in stimulation of cell proliferation by serotonin in human small cell lung carcinoma. Eur J Pharmacol Mol Pharmacol 1994; 268: 425-30.
7. Sheehan PFJ, Baker T, Tutton PJM, Barkla DH. Effects of histamine and 5-hydroxytryptamine on the growth rate of xenografted human bronchogenic carcinomas. Clin Exp Pharmacol Physiol 1996; 23: 465-71.
8. Hoosein NM, Bandyk MG, Nicolson GL, Logothesis CJ, Chung LWK. Expression of neuroendocrine markers and extracellular matrix degradative enzymes in human prostate tumour cells (abstract). J Urol 1993; 149: 479A.
9. Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 1994; 14: 1215-20.
10. Ishizuka L, Beauchamp RD, Townsend JC, Greeley GH, Thompson JC. Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. J Cell Physiol 1992; 150: 1-7.
11. Pratesi G, Cervi S, Balsari A, Bondiolotti G, Vicentini LM. Effect of serotonin and nicotine on the growth of a human small cell lung cancer xenograft. Anticancer Res 1996; 16: 3615-20.
12. Orvoine RH, Seidman JM. Induction of acute necrosis in Walker 256 tumours in rats. Cancer Res 1977; 37: 102-5.
13. Orvoine RH. Influence of various hexoses and vasoactive agents on osmotically induced oncolysis. Cancer Res 1981; 41: 5044-8.
14. Crile GJ. The effects of heat and radiation on cancers implanted on the feet of mice. Cancer Res 1963; 23: 372-80.
15. Manda T, Nishigaki F, Mori J, Shimomura K. Important role of serotonin in the antitumour effects of recombinant human tumour necrosis factor-alpha in mice. Cancer Res 1988; 48: 4250-5.
16. Stücker O, Vicaut E, Teisseire B. Specific response to 5-HT2 agonists by arterioles linked to Meth A tumours in mice. Am J Physiol 1992; 262: H704-9.
17. Burtin C, Scheinmann P, Salomon JC, Lespinats G, Canu P. Decrease in tumour growth by injection of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors. Br J Cancer 1982; 45: 54-61.
18. 2 agonists by tumour-feeding arterioles in mice: consequences for tumour growth. Int J Radiat Biol 1991; 60: 237-41.
19. Folkman J. Tumour angiogenesis. Adv Cancer Res 1985; 43: 175-203.
20. Cater DB, Schoeniger EL, Watkinson DA. Effect of breathing high pressure oxygen upon tissue oxygen tension in rat and mouse tumours. Acta Radiol Ther Phys Biol 1963; 1: 233-52.
21. Shrivastav S, Joines WT, Jirtle RL. Effect of 5-hydroxytryptamine on tissue blood flow and microwave heating of rat tumours. Cancer Res 1985; 45: 3203-8.
22. Majno G, Shea SM, Leventhal MS. Endothelial contraction induced by histamine-type mediators. An electron microscopic study. J Cell Biol 1969; 42: 647-72.
23. Laemmel E, Stücker O, Darmon PL, Vicaut E. Characterization of the specific response to serotonin of mouse tumour-feeding arterioles. Int J Radiat Biol 1998; 74: 379-86.
24. Lübbe AS, Huhnt W. Microvessel diameters of human colon adenocarcinoma during acute treatment with serotonin. Int J Microcirc 1994; 14: 218-25.
25. Stücker O, Laemmel E, Teisseire B, Vicaut E. Specific response of mouse tumour-feeding arterioles to stimulation by 5-HT1 agonists. Int J Radiat Oncol Biol Phys 1997; 37: 1125-31.
26. Sikorski BW, James GM, Glance SD, Hodgson WC, King RG. Effect of endothelium on diabetes-induced changes in constrictor responses mediated by 5-hydroxytryptamine in rat aorta. J Cardiovasc Pharmacol 1993; 22: 423-30.
27. 1-like receptors by endogenous nitric oxide. Br J Pharmacol 1995; 114: 969-74.
28. Valentin JP, Bonnafous R, John GW. Influence of the endothelium and nitric oxide on the contractile responses evoked by 5-HT1D receptor agonists in the rabbit isolated saphenous vein. Br J Pharmacol 1996; 119: 35-42.
29. Porsa E, Harper MJK, Herlihy JT. Effects of preload and eicosanoid synthesis inhibition on rat aortic smooth muscle sensitivity. Prostagland Leuk Essent Fatty Acids 1989; 38: 61-5.
30. Chester AH, Allen SP, Tadjkarimi S, Yacoub MH. Interaction between thromboxane A2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries. Circulation 1993; 87: 874-80.
31. Van Diest M, Verbeuren TJ, Herman AG. Vascular interaction between 5-hydroxytryptamine and 5-lipoxygenase metabolites of arachidonic acid. Eur J Pharmacol 1993; 231: 267-74.
32. Martin GR. Vascular receptors for 5-hydroxytryptamine: distribution, function, and classification. Pharmacol Ther 1994; 62: 283-324.
33. Yokota Y, Imaizumi Y, Asano M, Matsuda T, Watanabe M. Endothelium-derived relaxing factor released by 5-HT: distinct from nitric oxide in basilar arteries of normotensive and hypertensive rats. Br J Pharmacol 1994; 113: 324-30.
34. Lamping KG. Response of native and stimulated collateral vessels to serotonin. Am J Physiol 1997; 272: H2409-15.
35. 1 receptors. Int J Radiat Biol 1999; 75: 365-71.
36. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Blood flow failure as a major determinant in the antitumour action of flavone acetic acid (NSC 347512). J Natl Cancer Inst 1989; 81: 1005-13.
37. Baguley BC, Holdaway KM, Thomsem LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991; 27: 482-7.
38. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 1993; 29A: 1320-4.
39. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. The effect of vinca alkaloids on tumour blood flow. Adv Exp Med Biol 1994; 345: 417-22.
40. Baguley BC, Cole G, Thomsen LL, Zhuang L. Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1993; 33: 77-81.
41. Baguley BC, Zhuang L, Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol Res 1997; 9: 55-60.
42. Cater DB, Petrie A, Watkinson DA. Effect of 5-hydroxytryptamine and cyproheptadine on tumour blood flow. Acta Radiol Ther Phys Biol 1965; 3: 109-29.
43. Jenkins DC, Wilkinson J, Lindon JC, Farrant RD, Carpenter TA, Stables JN, et al. Anti-tumour effects of 5-hydroxytryptamine (5-HT) are not entirely attributable to its effects on tumour vasculature. Int J Radiat Biol 1991; 60: 243-8.
44. Knapp WH, Debatin J, Helus F, Sinn H-J, Ostertag H. Increased thermal response to ultrasound in the Walker carcinosarcoma treated with vasoactive drugs. Cancer Res 1989; 49: 1768-72.
45. Huhnt W, Lübbe AS. Venules and arterioles in xenotransplanted human colon adenocarcinoma critically constrict with hyperthermia and serotonin. J Cancer Res Clin Oncol 1995; 121: 267-74.
46. Brown JM, Giaccia AJ. The unique physiology of solid tumours: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-16.
47. Chaplin DJ. Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT). Br J Cancer 1986; 54: 727-31.
48. Lash CJ, Rutland M, Baguley BC, Wilson WR. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998; 78: 439-45.